Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
MicroRNAs01:22

MicroRNAs

21.6K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.6K
Antigen Processing Pathways01:31

Antigen Processing Pathways

1.3K
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
1.3K
Master Transcription Regulators02:23

Master Transcription Regulators

7.0K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.0K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

650
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
650

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infliximab-Responsive Severe Ulcerative Colitis With Pyoderma Gangrenosum After IL-6 and IGF-1 Blockade.

ACG case reports journal·2026
Same author

Association between the peptide spectrum match values of LGI1, ADAM22, ADAM23 and DLG4 in the immunoprecipitation products of five autoimmune encephalitis cases with LGI1 antibody: A case series.

Internal medicine (Tokyo, Japan)·2026
Same author

Inhibition of chemokine CXCL12 modulates the tumor microenvironment in glioblastoma and potentiates immune checkpoint inhibitor efficacy in a tissue-specific manner.

Neuro-oncology advances·2026
Same author

Infant weight gain and motor development in relation to childhood adiposity and physical activity.

JSAMS plus·2026
Same author

Infant gross motor development and childhood physical activity: Role of adiposity.

JSAMS plus·2026
Same author

Characteristic patterns of complement deposition in NMOSD, MOGAD, and MS.

Acta neuropathologica·2026

Related Experiment Video

Updated: Sep 6, 2025

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.6K

TRIM22 negatively regulates MHC-II expression.

Ayano Inoue1, Masashi Watanabe2, Takeshi Kondo2

  • 1Department of Biochemistry, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan; Department of Gastroenterological Surgery II, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.

Biochimica Et Biophysica Acta. Molecular Cell Research
|July 1, 2022
PubMed
Summary
This summary is machine-generated.

Tripartite motif-containing (TRIM) 22 negatively regulates major histocompatibility complex (MHC) class II expression in cancer cells. Inhibiting TRIM22 increases MHC-II levels, potentially enhancing cancer immunotherapy efficacy.

Keywords:
Checkpoint blockade immunotherapyIFN-γMHC-IITRIM22Ubiquitin

More Related Videos

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
08:10

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

8.7K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

9.9K

Related Experiment Videos

Last Updated: Sep 6, 2025

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.6K
Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
08:10

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

8.7K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

9.9K

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • Checkpoint blockade immunotherapy is a promising cancer treatment.
  • Enhancing T-cell activation via increased MHC class II on cancer cells can improve immunotherapy outcomes.

Purpose of the Study:

  • To investigate the role of tripartite motif-containing (TRIM) 22 in regulating major histocompatibility complex (MHC) class II expression.
  • To explore TRIM22 as a potential therapeutic target for enhancing cancer immunotherapy.

Main Methods:

  • Utilized CRISPR-Cas9 gene editing to knock out TRIM22 in cancer cells.
  • Overexpressed TRIM22 in cancer cells.
  • Quantified MHC class II protein and mRNA levels.
  • Assessed MHC class II protein degradation pathways.

Main Results:

  • TRIM22 knockout increased MHC class II protein levels, while TRIM22 overexpression decreased them.
  • TRIM22 did not affect MHC class II or CIITA mRNA levels.
  • TRIM22 knockout promoted, rather than suppressed, MHC class II protein degradation.
  • TRIM22 regulates MHC class II protein levels through mechanisms beyond transcription or degradation.

Conclusions:

  • TRIM22 negatively regulates MHC class II protein expression via non-transcriptional and non-degradative pathways.
  • Inhibiting TRIM22 increases MHC class II expression in cancer cells.
  • Targeting TRIM22 offers a potential strategy to potentiate checkpoint blockade immunotherapy.